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Purpose: To evaluate the outcomes of adjuvant radiotherapy (RT) and to analyze prognostic factors of survival in the International 
Federation of Gynecology and Obstetrics (FIGO) IB-IIA uterine cervical cancer.
Materials and Methods: We retrospectively reviewed the medical records of 148 patients with FIGO IB-IIA uterine cervical 
cancer who underwent surgery followed by adjuvant RT at the Yonsei Cancer Center between June 1997 and December 2011. 
Adjuvant radiotherapy was delivered to the whole pelvis or an extended field with or without brachytherapy. Among all patients, 
57 (38.5%) received adjuvant chemotherapy either concurrently or sequentially. To analyze prognostic factors, we assessed 
clinicopathologic variables and metabolic parameters measured on preoperative 18F-fluorodeoxyglucose (FDG) positron emission 
tomography/computed tomography (PET/CT). To evaluate the predictive performance of metabolic parameters, receiver operating 
characteristic curve analysis was used. Overall survival (OS) and disease-free survival (DFS) were analyzed by the Kaplan-Meier 
method.
Results: The median follow-up period was 63.2 months (range, 2.7 to 206.8 months). Locoregional recurrence alone occurred 
in 6 patients, while distant metastasis was present in 16 patients, including 2 patients with simultaneous regional failure. The 
5-year and 10-year OSs were 87.0% and 85.4%, respectively. The 5-year and 10-year DFSs were 83.8% and 82.5%, respectively. In 
multivariate analysis, pathologic type and tumor size were shown to be significant prognostic factors associated with both DFS 
and OS. In subset analysis of 40 patients who underwent preoperative PET/CT, total lesion glycolysis was shown to be the most 
significant prognostic factor among the clinicopathologic variables and metabolic parameters for DFS.
Conclusion: Our results demonstrated that adjuvant RT following hysterectomy effectively improves local control. From the 
subset analysis of preoperative PET/CT, we can consider that metabolic parameters may hold prognostic significance in early uterine 
cervical cancer patients. More effective systemic treatments might be needed to reduce distant metastasis in these patients.
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Introduction
Early stage cervical cancer can be effectively treated with 
radical hysterectomy or definitive radiotherapy. According to 
previous reports, the 5-year survival rates of the International 
Federation of Gynecology and Obstetrics (FIGO) stage IB-IIA 
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cervical cancer patients who undergo surgery range from 83% 
to 91%, while those of patients treated with radiotherapy (RT) 
alone range from 74% to 91% [1,2]. Although patients with 
early cervical cancer achieve relatively good survival rates, 
about 20% of all early cervical cancer patients still experience 
treatment failures. 
To reduce treatment failure, adjuvant treatments have been 
applied in consideration of clinical and pathologic risk factors 
for recurrence. Several studies have identified several risk 
factors associated with increased recurrence and mortality, 
including pelvic lymph node metastasis, parametrial invasion, 
and positive surgical margins as high risk factors [3,4]. 
Moreover, patients with large tumor diameter, lymphovascular 
space involvement, or deep stromal invasion are considered to 
be at intermediate risk of recurrence [5-7]. 
The Gynecologic Oncology Group phase III trial (GOG 92) 
evaluated the benefits and risk of adjuvant pelvic RT aimed at 
reducing recurrence in women with stage IB cervical cancer 
treated by radical hysterectomy and pelvic lymphadenectomy 
[6,7]. In the study, adjuvant RT significantly reduced the risk 
of recurrence and prolonged progression-free survival (PFS) 
in intermediate-risk patients with cervical cancer. In regards 
to high-risk patients, a phase III study (GOG 109/SWOG 8797) 
demonstrated that addition of cisplatin-based concurrent 
chemotherapy to postoperative RT significantly improves 
patient survival [8]. 
Nowadays, functional imaging modalities, such as 18F- 
fluorodeoxyglucose (FDG) positron emission tomography/
computed tomography (PET/CT), are commonly used as 
optional imaging studies for initial tumor staging, optimization 
of treatment, and detection of tumor recurrence in patients 
with uterine cervical cancer. FDG-PET/CT can also be performed 
to evaluate treatment responses, since FDG uptake is correlated 
with the viable tumor burden [9,10]. Moreover, some studies 
have suggested that metabolic responses on FDG-PET/CT are 
associated with good survival outcome in cervical cancer [4,11].
In this study, we investigated the outcomes of adjuvant RT 
and analyzed prognostic factors of survival and prognostic value 
of metabolic parameters in FIGO IB-IIA uterine cervical cancer 
patients.
Materials and Methods
1. Patients
Between 1997 and 2011, a total of 350 patients diagnosed with 
uterine cervix cancer underwent curative hysterectomy with or 
without pelvic lymph node dissection (PLND) and para-aortic 
node sampling (PALNS), followed by adjuvant radiotherapy, at 
Yonsei Cancer Center, Yonsei University College of Medicine 
(Seoul, Korea). Among the treated patients, those who were 
diagnosed with pathologic FIGO stage IB-IIA uterine cervical 
cancer were included, while patients who received neoadjuvant 
chemotherapy or RT or who had a history of other malignancy 
were excluded from the study. Finally, a total of 148 patients 
were included and their medical records were reviewed 
retrospectively. 
2. Pretreatment evaluation
The routine procedure for staging included a physical 
examination, common laboratory tests, standard chest 
radiographs, intravenous pyelograms, barium enemas, 
cystoscopies, and sigmoidoscopies. FIGO staging was 
determined according to baseline study findings, gynecologic 
pelvic exam, and additional imaging studies, such as CT, 
MRI, or PET/CT. Metabolic parameters, such as maximum 
standardized uptake value (SUVmax), mean standardized 
uptake value (SUVmean), metabolic tumor volume (MTV), 
and total lesion glycolysis (TLG) for the primary tumor, were 
measured on preoperative FDG-PET/CT. The SUV of the tumor 
was normalized to that of the background level in the middle 
of the ascending aorta to minimize the confounding effects of 
inter-scan variations in SUV measurement. MTV was delineated 
by auto-threshold at 1.5 times the background level in the 
aorta, followed by knowledge based manual editing. Maximum 
and mean SUVs normalized to the background level were 
computed. TLG was calculated as the product of the lesion 
SUVmean and MTV. 
3. Surgery
Table 1 lists the treatment details. All patients underwent 
radical hysterectomies. Patients who underwent conization or 
type I hysterectomy were excluded. PLND was performed in 
136 patients (91.9%), and para-aortic lymph node sampling/
dissection (PALNS/D) was performed in 88 patients (59.5%). 
Risk factors, such as resection margin, lymphovascular invasion 
(LVI), stromal invasion depth, and the extent of pelvic or para-
aortic lymph node (PALN) metastasis, were documented in 
surgical pathology reports.
4. Radiotherapy
Adjuvant radiotherapy was initiated within 3–4 weeks after 
surgery and delivered to the whole pelvis field. Extended field 
radiotherapy or brachytherapy was performed as necessary 
based on the decision of the radiation oncologist. Especially, 
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brachytherapy was performed to reduce external beam 
radiotherapy (EBRT) dose to 41.4–45 Gy giving sufficient 
dose for vaginal vault with brachytherapy in order to reduce 
late complication of EBRT. Extended field radiotherapy was 
performed for patients with para-aortic lymph node metastasis 
or high level pelvic node metastasis. The superior border of 
the whole pelvis field was at the L4-L5 interspace, and thus, 
included all of the external iliac and hypogastric lymph nodes. 
The inferior border was either at the lower border of the 
ischial tuberosity or the lower border of the obturator foramen 
depending on the extension of the vagina. The lateral portal 
anterior margin was plated at the pubic symphysis, and the 
posterior margin was at the S2–S3 interspace. Whole-pelvis 
and extended-field irradiation were performed in 135 patients 
(91.2%) and 13 patients (8.8%), respectively. External beam 
irradiation up to a median of 50.4 Gy (range, 39.6 to 54.0 Gy) 
was delivered five times per week with a dose of 1.8 Gy per 
fraction. In 40 patients (27%) treated with combined external 
irradiation and brachytherapy, high-dose rate intracavitary 
irradiation was applied using a remote afterloading system 
with Ir-192 as the source up to a median of 12 Gy (range, 9 to 
30 Gy) at 3–5 Gy per fraction.
5. Chemotherapy
Adjuvant chemotherapy was performed in 57 patients (38.5%) 
either concurrently or sequentially according to the preference 
of the gynecological oncologist. A number of chemotherapy 
regimens were used, most frequently with cisplatin-based 
regimens in 38 patients (66.7%). Weekly cisplatin was used 
in 12 patients (8.1%), while cisplatin was sometimes used in 
Table 1. Treatment profiles (n = 148)
Characteristic Value
BPLND
   No
   Yes
PALNS/D
   No
   Yes
Adjuvant treatment scheme
   RT alone
   CRT
RT field
   WP
   WP + Brachytherapy
   Extended field
RT Dose (Gy)
   EBRT
   Brachytherapy
   Total
Chemotherapy regimen
   Cisplatin-based
   Paclitaxel/carboplatin
   Other
 
12 (8.1)
136 (91.9)
 
60 (40.5)
88 (59.5)
 
91 (61.5)
57 (38.5)
 
95 (64.2)
40 (27.0)
13 (8.8)
 
50.4 (39.6–54.0)
12.0 (9.0–30.0)
50.4 (41.4–80.4)
 
38 (66.7)
16 (28.0)
3 (5.3)
Values are presented as median (range) or number of patients (%).
BPLND, bilateral pelvic lymph node dissection; PALNS/D, para-
aortic lymph node sampling/dissection; RT, radiotherapy; CRT, 
chemoradiation therapy; WP, whole pelvis; EBRT, external beam 
radiotherapy.
Table 2. Patient characteristics (n = 148)
Characteristic Value
Age (yr)
pFIGO stage
   IB1
   IB2
   IIA1
   IIA2
Pathologic type
   SCC
   Non-SCCa)
Tumor size (cm)
   <5 
   ≥5 
   Unevaluated
Resection margin
   Negative
   Positive
LVI
   Negative
   Positive
Stromal invasion depth
   <1/3
   1/3–2/3
   >2/3
   Unevaluated
Pelvic LN metastasis
   Negative
   Positive
   Unevaluated
PALN metastasis
   Negative
   Positive
   Unevaluated
48 (28–80)
 
97 (65.5)
22 (14.9)
24 (16.2)
5 (3.4)
 
103 (69.6)
45 (30.4)
 
119 (80.4)
16 (10.8)
13 (8.8)
 
133 (89.9)
15 (10.1)
 
51 (34.5)
97 (65.5)
 
18 (12.2)
54 (36.5)
67 (45.3)
9 (6.0)
 
65 (43.9)
71 (48.0)
12 (8.1)
 
83 (56.1)
5 (3.4)
60 (40.5)
Values are presented as median (range) or number of patients (%).
FIGO, International Federation of Gynecology and Obstetrics; 
pFIGO, pathologic FIGO stage; SCC, squamous cell carcinoma; LVI, 
lymphovascular invasion; PALN, para-aortic lymph node.
a)Non-SCC group consists of 10 adenosquamous cell carcinomas, 
29 adenocarcinomas, and 6 mixed type.
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combination with vincristine (7.4%), 5-fluorouracil (6.7%), 
or other regimens (2.7%). Paclitaxel/carboplatin combination 
therapy was used in 16 patients (28.0%).
6. Statistical analyses
Overall survival (OS) was measured from the date of diagnosis 
to the date of death from any cause or the date at last clinical 
follow-up. Disease-free survival (DFS) was defined as the time 
between the date of diagnosis and the first recurrence of the 
disease or any death. OS and DFS were assessed using the 
Kaplan-Meier method. For multivariate analysis of prognostic 
factors, separate Cox proportional hazards regression 
models were utilized to estimate the relationship between 
each variables and OS or DFS. To evaluate the predictive 
performance of metabolic parameters, we conducted time-
dependent receiver operating characteristic (ROC) curve 
analysis for censored survival data and assessed the area 
under the ROC curve (AUC). A two-sided p-value less than 0.05 
was considered statistically significant. 
Results
1. Patient characteristics 
Patient characteristics are shown in Table 2. The median 
patient age was 48 years (range, 28 to 80 years). The majority 
of patients (97 of 148 patients, 65.5%) were pathologic FIGO 
(pFIGO) stage IB1. Risk groups were defined using the same 
definitions used for the GOG phase III study (GOG 92) [6,7]. A 
total of 67 patients were categorized as the high-risk group 
and 81 patients were categorized as the low-intermediate risk 
group. The most common histopathologic type was squamous 
cell carcinoma (SCC, 69.6%). Table 2 shows the details of 
patient characteristics including age, pFIGO stage, pathologic 
type, tumor size (<5 cm or ≥5 cm), resection margin, LVI, 
stromal invasion depth, and pelvic or PALN metastasis. Patients 
who did not undergo PLND or PALNS/D were assigned to the 
unevaluated group.
2. Patterns of failures
The median follow-up time was 63.2 months (range, 2.7 to 
206.8 months). Twenty patients (13.5%) experienced treatment 
failures after completion of their respective treatments. A 
detailed distribution of treatment failure patterns is shown 
in Fig. 1. Local failure occurred in 3 patients, while regional 
failure and distant metastasis occurred in 3 and 16 patients, 
Regional
failure
(2.0%)
Distant
metastasis
(10.8%)
3
1 14
0
0
0
2
Local failure
(2.0%)
Fig. 1. Patterns of failures.
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Fig. 2. Kaplan-Meier overall survival (A) and disease-free survival (B) curves.
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respectively. In 2 patients, both regional failure and distant 
metastasis were observed simultaneously. 
3. Survival outcomes and prognostic factors
Among all of the patients, the 5-year and 10-year OSs were 
87.0% and 85.4%, respectively. The 5-year and 10-year DFSs 
were 83.8% and 82.5%, respectively (Fig. 2). In univariate 
analysis, pathologic type, tumor size, and PALN involvement 
were significantly associated with DFS (p = 0.075, p = 0.005, 
and p = 0.002, respectively) (Table 3). OS was also affected 
by pathologic type, tumor size, and PALN involvement, the 
same as in the analysis of DFS. Different risk groups did not 
show statistically significant differences for either OS or 
DFS. Similarly, the use of concurrent chemoradiation therapy 
(CRT) was not a statistically significant prognostic factor with 
respect to OS and DFS.
In multivariate analysis, pathologic type and tumor size 
were shown to be prognostic factors significantly associated 
with both DFS and OS. The hazard ratios (HRs) of non-SCC 
pathologic type and large tumor size (≥4 cm) were 3.78 (95% 
confidence interval [CI], 1.10 to 13.03; p = 0.035) and 5.66 (95% 
CI, 1.56 to 20.57; p = 0.008), respectively. 
4. Prognostic value of metabolic parameters
Preoperative PET/CT was performed in 40 of 148 patients. For 
metabolic parameters, such as SUVmax, SUVmean, MTV, and 
Table 3. Prognostic analysis of disease-free survival and overall survival
Variable Subgroup
DFS OS
Univariate Multivariate Univariate Multivariate
p-value HR (95% CI) p-value p-value HR (95% CI) p-value
Pathologic type
Tumor size (cm)
Pelvic LN involvement
PALN involvement
Resection margin
LVI
CRT
Risk group
SCC vs. non-SCC
<4 vs. ≥4
No vs. yes
No vs. yes
No vs. yes
No vs. yes
No vs. yes
Low-intermediate vs. high
0.075
0.005
0.375
0.002
0.593
0.312
0.857
0.837
3.28 (1.08–9.91)
3.23 (1.03–10.09)
-
2.51 (0.50–12.67)
-
-
-
-
0.040
0.044
-
0.265
-
-
-
-
0.033
<0.001
0.153
0.007
0.934
0.064
0.627
0.394
3.78 (1.10–13.03)
5.66 (1.56–20.57)
-
1.78 (0.33–9.73)
-
-
-
-
0.035
0.008
-
0.506
-
-
-
-
DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; SCC, squamous cell carcinoma; LN, lymph node; 
PALN, para-aortic lymph node; LVI, lymphovascular invasion; CRT, chemoradiation therapy.
Table 4. Prognostic factors for DFS in patients with PET/CT
Variable Subgroup
DFS
Univariate Multivariate
p-value HR (95% CI) p-value
Pathologic type
Tumor size (cm)
Pelvic LN involvement
PALN involvement
Resection margin
LVI
CRT
Risk group
SUVmax
SUVmean
TLG (cm3)
MTV (g)
SCC vs. non-SCC
<4 vs. ≥4
No vs. yes
No vs. yes
No vs. yes
No vs. yes
No vs. yes
Low-intermediate vs. high
<4.55 vs. ≥4.55
<3.15 vs. ≥3.15
<191304 vs. ≥191304
<12.695 vs. ≥12.695
0.009
0.144
0.741
<0.001
0.443
0.665
0.645
0.492
0.212
0.248
0.001
0.112
6.56 (0.67–63.75)
-
-
1.83 (0.50–6.75)
-
-
-
-
-
-
18.745 (1.30–270.24)
-
0.105
-
-
0.365
-
-
-
-
-
-
0.031
-
DFS, disease-free survival; PET/CT, positron emission tomography/computed tomography; HR, hazard ratio; CI, confidence interval; LN, 
lymph node; PALN, para-aortic lymph node; LVI, lymphovascular invasion; CRT, chemoradiation therapy; SUVmax, maximum standard-
ized uptake value; SUVmean, mean standardized uptake value; TLG, total lesion glycolysis; MTV, metabolic tumor volume.
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TLG, we intended to analyze their prognostic value. Among 
these patients, death occurred in only 1 patient, and recurrence 
occurred in 5 patients. Locoregional recurrence occurred in 2 
patients, while distant metastasis was present in 4 patients, 
including 1 patient with simultaneous regional failure. The 
median SUVmax and the median SUVmean were 7.1 (range, 2.7 
to 38.8) and 3.9 (range, 2.6 to 10.3). ROC analysis identified a 
cutoff of 4.55 for SUVmax (AUC = 0.583; p = 0.135; 95% CI, 
0.318 to 0.848) and 3.15 for SUVmean (AUC = 0.571; p = 0.131; 
95% CI, 0.314 to 0.829). Cutoff values for MTV and TLG were 
measured as 12.695 (AUC = 0.623; p = 0.137; 95% CI, 0.355 to 
0.891) and 191304.5 (AUC = 0.629; p = 0.151; 95% CI, 0.333 to 
0.925), respectively. Based on the ROC curve analysis, patients 
could be divided into two groups. In univariate analysis 
of clinicopathologic variables and metabolic parameters, 
pathologic type (p = 0.009), PALN involvement (p < 0.001), 
and TLG (p = 0.001) were identified as prognostic factors for 
DFS (Table 4, Fig. 3). In multivariate analysis, TLG was the only 
prognostic factor for DFS (p = 0.031; HR = 18.745; 95% CI, 1.30 
to 270.24). For OS, pathologic type (p = 0.001), tumor size (p = 
0.015), PALN involvement (p < 0.001), and TLG (p = 0.001) were 
identified as prognostic factors in univariate analysis; however, 
no variable was identified as significant in multivariate 
analysis.
Discussion and Conclusion
Radical hysterectomy with pelvic lymphadenectomy provides 
curative surgical excision and exhibits survival rates of 
more than 80% for stage IB and IIA cervical carcinoma. 
Adjuvant radiotherapy is thought to improve local control 
and overall survival in the remainder of patients. In our study, 
high locoregional control was achieved through adjuvant 
radiotherapy following surgery in early stage cervical cancer 
FIGO IB–IIA. Distant metastasis comprised the majority of 
treatment failures in our study. The addition of adjuvant 
chemotherapy to radiotherapy was not beneficial with 
respect to decreasing distant metastasis in our patients. These 
findings might be explained by the fact that the chemotherapy 
regimens were heterogeneous and the aim of concurrent 
chemotherapy with radiotherapy was not to improve systemic 
control but to achieve a radiosensitizing effect. Additionally, 
the number of patients who experienced distant failures was 
too small to show any statistically significant difference in our 
study. 
In our study, pathologic type and tumor size were shown to 
be significant prognostic factors associated with both DFS and 
OS in multivariate analysis. This result is well correlated with 
several previous studies that reported on independent risk 
factors frequently associated with increased cancer recurrence 
and mortality [12-14]. In the present study, large tumor size 
was the most significant prognostic factor for worse OS, 
with a HR of 5.7, which is consistent with the results of other 
studies. Chung et al. [13] reported that cervical cancer larger 
than 4 cm in diameter determined by preoperative palpation 
was associated with a 5-fold increase in pelvic lymph node 
metastasis, a 10-fold increase in recurrence, and a 50% 
decrease in survival. Additionally, in our study, non-SCC type 
was associated with a 3.8-fold increase in cancer specific 
death, compared to SCC type. Several previous retrospective 
studies have reported that patients with adenocarcinoma have 
a poorer prognosis than patients with SCC [12,14-16], whereas 
other studies have found no difference in survival between 
these two subtypes [1,5,13,17]. We previously reported that 
the 5-year OS and PFS of adenocarcinoma are much worse 
than those for SCC [18]. Mabuchi et al. [19] also reported that 
adenocarcinoma shows worse survival than SCC in early stage 
cervical cancer patients with intermediate- and high-risk 
factors, regardless of the type of adjuvant radiotherapy used 
after radical hysterectomy.
We also analyzed the outcomes of different risk groups 
(low-intermediate vs. high-risk) and the effect of adding 
chemotherapy to adjuvant radiotherapy. The 5-year OSs of the 
low-intermediate risk group and high-risk group were 89.2% 
and 85.1%, respectively. The high-risk group exhibited worse 
survival outcomes than the low-intermediate risk group; 
however, risk stratification was not identified as a significant 
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Fig. 3. Kaplan-Meier disease-free survival curve for total lesion 
glycolysis (TLG).
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prognostic factor in either univariate or multivariate analysis. 
Likewise, addition of chemotherapy was not a significant 
prognostic factor in OS or PFS. In the GOG 109 trial, the 
addition of concurrent cisplatin-based chemotherapy to RT 
significantly improved PFS and OS for high-risk early-stage 
cervical cancer patients who underwent radical hysterectomy 
and pelvic lymphadenectomy [8]. Several other retrospective 
studies also concluded that adjuvant CRT is beneficial in 
intermediate risk groups [17,20]. However, in the present 
study, adjuvant CRT failed to show a benefit on PFS and OS. 
This result might be due to including more patients from the 
high-risk group in the adjuvant CRT group, compared with the 
RT-only group (61.9% vs. 34.9%). The currently ongoing GOG 
263 trial aims to determine if adjuvant CRT can significantly 
improve recurrence free survival, compared to radiation 
therapy alone, in intermediate-risk FIGO stage I–IIA cervical 
cancer patients.
We also evaluated the prognostic significance of metabolic 
parameters on preoperative PET/CT. In multivariate analysis, 
TLG was identified as the only prognostic factor for DFS, 
among the clinicopathologic variables and metabolic 
parameters, and no significant factor was identified for OS. 
Several studies have also investigated associations between 
prognosis and metabolic parameters on preoperative FDG-PET/
CT data in primary cervical tumor mass, lymph nodes, and the 
uterine body [3,21]. These previous studies have described SUV 
as a predictor of poor prognosis. However, since SUV values 
only represent metabolic activity, tumor size and SUV cannot 
be considered together. In our study, TLG was identified as a 
significant prognostic factor, suggesting that both metabolic 
activity and volumetric parameters are important to predicting 
prognosis. This result indicates that metabolic parameters may 
hold prognostic significance in early uterine cervical cancer 
patients. However, further well-designed large scale studies are 
needed to definitively conclude the prognostic value of these 
metabolic parameters.
This study has limitations that stem from its retrospective 
nature. The use of chemotherapy, chemotherapy regimens, 
and radiation doses were not uniform, which may have 
affected tumor responses, although no statistically significant 
differences were found. Also, treatment related toxicities 
could not evaluated objectively due to lack of medical records 
about toxicities. Since PET/CT was performed as an optional 
imaging study for uterine cervical cancer patients, PET/CT was 
performed in only 40 of our study patients. In these patients, 
only one patient died and only five recurrences occurred. 
Due to this small number of events, it was difficult to assess 
significant factors associated with OS. Nevertheless, this study 
has its strengths, in that a large number of patients were 
analyzed and a long-term follow-up was achieved for these 
patients. Additionally, our results suggested the usefulness of 
metabolic parameters in early uterine cervical cancer patients, 
even though only a small number of patients were analyzed. 
In conclusion, our results demonstrated that adjuvant RT 
following hysterectomy effectively improves local control; 
meanwhile, CRT was not effective in preventing distant 
metastasis in patients with pathologic FIGO stage IB–IIA 
uterine cervical cancer. Through an analysis of preoperative 
PET/CT, we could consider that metabolic parameters may 
hold prognostic significance in early uterine cervical cancer 
patients. More effective systemic treatments might be needed 
to reduce distant metastasis in these patients.
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